Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products include MX-ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HRM kits and ICP liquid biopsy testing. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.